SCHEMBL6258918

SCHEMBL6258918

CCN(Cc1ccccc1NCc1ccccc1)c1ccc(C(=O)O)nn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ ASPH Q12797 2/20 0.41
▸ KDM8 Q8N371 2/20 0.41
▸ RIOX2 Q8IUF8 1/20 0.41
▸ KDM6B O15054 1/20 0.38
▸ KDM4A O75164 1/20 0.38
▸ KDM4D Q6B0I6 1/20 0.38
▸ KDM4C Q9H3R0 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.37
▸ PLK1 P53350 1/20 0.37
▸ HSD17B10 Q99714 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ CTDSP1 Q9GZU7 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ TYK2 P29597 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6259742 0.91 JAK3 (0.41) ENPP2KDM4EASPHKDM8RIOX2
SCHEMBL6258056 0.89 ENPP2 (0.41) ENPP2KDM4EASPHKDM8RIOX2
SCHEMBL6259172 0.75 SLC6A4 (0.47) ENPP2L3MBTL1
SCHEMBL4868816 0.72 PTGER1 (0.54) —
SCHEMBL893345 0.69 HSD17B10 (0.60) KDM4EHDAC8HSD17B10ALDH1A1POLB
SCHEMBL12427630 0.67 PLK1 (0.48) KDM4EASPHKDM8RIOX2KDM6B
SCHEMBL7803732 0.65 MAPT (0.40) ENPP2KDM4EALDH1A1HPGD
SCHEMBL7812547 0.65 RXRA (0.38) ENPP2KDM4EALDH1A1HPGD
SCHEMBL7662551 0.65 HPGD (0.42) KDM4EPOLBHPGD
SCHEMBL11217423 0.65 HSD17B10 (0.55) KDM4EKDM6BKDM4AKDM4DKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5834468-A ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES ZENECA LIMITED (GB) 1998-11-10 — — US claimed
EP-0752421-B1 Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists ASTRAZENECA AB (SE) 2005-10-12 — — EP disclosed
US-6787562-B2 ANALGESICS; OSTEOPOROSIS ZENECA LTD. (GB) 2004-09-07 — — US disclosed
US-20030139418-A1 Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists SYNGENTA LIMITED (GB) 2003-07-24 — — US disclosed
US-6057345-A ANTAGONISTS OF THE PAIN ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS; USED IN PAIN RELIEF ZENECA LIMITED (GB) 2000-05-02 — — US disclosed
US-5834468-A ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES ZENECA LIMITED (GB) 1998-11-10 — — US disclosed
EP-0752421-A1 Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists ZENECA LIMITED (GB) 1997-01-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139418-A1 Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists PTGER1, PTGDR, PTGER2 ENPP2 301/4885KDM4E 3172/4885ASPH 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback